For the past several years, EuroPCR, the largest interventional cardiology conference in Europe, has been the coming out party for the two hottest technologies: first, all the talk was of TAVI (transcatheter aortic valve implantation), then last year, renal denervation dominated the scene. These major new product introductions generated significant buzz among both clinicians and industry officials eager to understand and promote these technologies. This year’s conference in Paris in May was a bit more business-as-usual, lacking the hype that accompanied recent meetings.
That is not to say that EuroPCR 2013 did not have the usual share of interesting technologies and clinical presentations from a stellar global faculty. Indeed, despite the decline in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?